MX375706B - Compuestos de inhibidor de autotaxina. - Google Patents

Compuestos de inhibidor de autotaxina.

Info

Publication number
MX375706B
MX375706B MX2016006623A MX2016006623A MX375706B MX 375706 B MX375706 B MX 375706B MX 2016006623 A MX2016006623 A MX 2016006623A MX 2016006623 A MX2016006623 A MX 2016006623A MX 375706 B MX375706 B MX 375706B
Authority
MX
Mexico
Prior art keywords
compounds
inhibitor compounds
autotaxin inhibitor
autotaxin
methods
Prior art date
Application number
MX2016006623A
Other languages
English (en)
Other versions
MX2016006623A (es
Inventor
David Lonergan
John Howard Hutchinson
Original Assignee
Sabre Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sabre Therapeutics Llc filed Critical Sabre Therapeutics Llc
Publication of MX2016006623A publication Critical patent/MX2016006623A/es
Publication of MX375706B publication Critical patent/MX375706B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se describen compuestos que son inhibidores de autotaxina, métodos para elaborar dichos compuestos, composiciones farmacéuticas y medicamentos que comprenden dichos compuestos, y métodos para utilizar dichos compuestos en el tratamiento de afecciones, enfermedades, o trastornos asociados con actividad autotaxina.
MX2016006623A 2013-11-22 2014-11-20 Compuestos de inhibidor de autotaxina. MX375706B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907965P 2013-11-22 2013-11-22
US201462038121P 2014-08-15 2014-08-15
PCT/US2014/066706 WO2015077503A1 (en) 2013-11-22 2014-11-20 Autotaxin inhibitor compounds

Publications (2)

Publication Number Publication Date
MX2016006623A MX2016006623A (es) 2017-03-10
MX375706B true MX375706B (es) 2025-03-06

Family

ID=53180152

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006623A MX375706B (es) 2013-11-22 2014-11-20 Compuestos de inhibidor de autotaxina.
MX2020009780A MX2020009780A (es) 2013-11-22 2016-05-20 Compuestos de inhibidor de autotaxina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020009780A MX2020009780A (es) 2013-11-22 2016-05-20 Compuestos de inhibidor de autotaxina.

Country Status (31)

Country Link
US (7) US9334261B2 (es)
EP (2) EP3071561B1 (es)
JP (1) JP6501367B2 (es)
KR (2) KR102367876B1 (es)
CN (2) CN105793253B (es)
AU (2) AU2014352888B2 (es)
BR (1) BR112016010220B1 (es)
CA (1) CA2930737C (es)
CL (1) CL2016001231A1 (es)
CR (2) CR20160289A (es)
CY (1) CY1124407T1 (es)
DK (1) DK3071561T3 (es)
EA (1) EA030068B1 (es)
ES (1) ES2875899T3 (es)
HR (1) HRP20210957T1 (es)
HU (1) HUE055213T2 (es)
IL (2) IL245383B (es)
LT (1) LT3071561T (es)
MX (2) MX375706B (es)
MY (1) MY182095A (es)
NI (1) NI201600071A (es)
NZ (1) NZ720478A (es)
PE (1) PE20160654A1 (es)
PH (1) PH12016500862B1 (es)
PL (1) PL3071561T3 (es)
PT (1) PT3071561T (es)
RS (1) RS62027B1 (es)
SI (1) SI3071561T1 (es)
SM (1) SMT202100531T1 (es)
WO (1) WO2015077503A1 (es)
ZA (2) ZA201603083B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2861566T1 (sl) 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
SG11201500572YA (en) 2012-09-25 2015-02-27 Hoffmann La Roche New bicyclic derivatives
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
US9951026B2 (en) 2013-09-17 2018-04-24 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
WO2015042053A1 (en) 2013-09-17 2015-03-26 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
WO2015048301A1 (en) 2013-09-26 2015-04-02 Pharmakea, Inc. Autotaxin inhibitor compounds
PT3071561T (pt) 2013-11-22 2021-06-25 Sabre Therapeutics Llc Compostos inibidores de autotaxina
MX2016006688A (es) 2013-11-22 2016-11-29 Pharmakea Inc Inhibidores tetraciclicos de autotaxina.
NO3074400T3 (es) 2013-11-26 2018-04-14
SG11201607845RA (en) 2014-03-26 2016-10-28 Hoffmann La Roche Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
KR20160128345A (ko) 2014-03-26 2016-11-07 에프. 호프만-라 로슈 아게 오토탁신(atx) 및 리소포스파티드산(lpa) 생성 억제제로서 이환형 화합물
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CA2986759C (en) * 2015-05-27 2025-06-17 Sabre Therapeutics Llc AUTOTAXIN INHIBITORS AND THEIR USES
JP6886967B2 (ja) 2015-09-04 2021-06-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ フェノキシメチル誘導体
JP6876685B2 (ja) 2015-09-24 2021-05-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ａｔｘ阻害剤としての二環式化合物
KR20180054634A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 신규한 이환형 화합물
EP3353181B1 (en) 2015-09-24 2021-08-11 F. Hoffmann-La Roche AG Bicyclic compounds as dual atx/ca inhibitors
KR20180054830A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서의 이환형 화합물
US11000142B2 (en) 2016-12-06 2021-05-11 John Joseph Girard Flexible floor mat incorporating LED lighting
CR20190423A (es) 2017-03-16 2019-11-01 Hoffmann La Roche Nuevos compuestos biciclícos como inhibidores dobles de atx/ca
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
CA3074111A1 (en) 2017-08-28 2019-03-07 Angiex, Inc. Anti-tm4sf1 antibodies and methods of using same
US12428477B2 (en) 2019-02-27 2025-09-30 Angiex, Inc. Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same
JP2025516335A (ja) * 2022-05-03 2025-05-27 セイバー セラピューティクス エルエルシー オートタキシン阻害剤の多形形態
CN116239577A (zh) * 2023-03-27 2023-06-09 沈阳药科大学 一种制备Cudetaxestat的方法
CN116396205B (zh) * 2023-04-20 2024-10-01 沈阳药科大学 一种n-芳基吲哚衍生物及其制备方法和应用

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210574A (en) 1991-03-08 1993-05-11 Mita Industrial Co., Ltd. Photosensitive drum body-mounting mechanism including a drive coupling member with a coupling protrusion adapted to bite into the inner surface of the mechanism's photosensitive drum
US5186522A (en) 1991-09-24 1993-02-16 Midland Brake, Inc. Air dryer purge line
JP3274468B2 (ja) 1992-11-10 2002-04-15 キャタピラー インコーポレイテッド ソレノイドバルブ組立体
US5407368A (en) 1992-12-15 1995-04-18 Minnesota Mining And Manufacturing Company Electrode connector
US5761473A (en) 1993-01-08 1998-06-02 International Business Machines Corporation Method and system for increased instruction synchronization efficiency in a superscalar processsor system utilizing partial data dependency interlocking
US5564949A (en) 1995-01-05 1996-10-15 Thomas & Betts Corporation Shielded compact data connector
JP2664048B2 (ja) 1995-03-27 1997-10-15 科学技術庁金属材料技術研究所長 六フッ化二ケイ素の合成法
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
CA2386750A1 (en) 1999-10-22 2001-05-03 Merck & Co. Inc. Pharmaceuticals for treating obesity
US6890933B1 (en) 2000-02-24 2005-05-10 President And Fellows Of Harvard College Kinesin inhibitors
CA2423312A1 (en) 2000-10-03 2002-04-11 Lilly Icos Llc Condensed pyridoindole derivatives
AR035857A1 (es) 2001-04-11 2004-07-21 Novirio Pharmaceuticals Ltd Fenilindoles; sus composiciones farmaceuticas y sus usos
SI1438289T1 (es) 2001-09-27 2005-08-31 Hoffmann La Roche
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
WO2004020409A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
CA2495915A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
CA2524054C (en) 2003-05-19 2012-04-24 Irm Llc Immunosuppressant compounds and compositions
BRPI0417858B1 (pt) 2003-12-23 2017-10-10 H. Lundbeck A/S Derivative compounds of aniline and pharmaceutical composition that understand it
CN1957117A (zh) 2004-05-19 2007-05-02 住友电气工业株式会社 Ⅲ族氮化物半导体晶体和其制造方法以及ⅲ族氮化物半导体器件
KR101141650B1 (ko) 2004-09-30 2012-05-17 엘지전자 주식회사 매체접속제어 계층에서의 데이터 처리 방법 및 이동통신용단말
WO2006041961A1 (en) 2004-10-05 2006-04-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US20080319044A1 (en) 2004-11-01 2008-12-25 Nuada, Llc Compounds and Methods of Use Thereof
US20060270634A1 (en) 2005-05-06 2006-11-30 Miller Duane D Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors
AR054394A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
WO2007041600A2 (en) 2005-10-03 2007-04-12 Luminescent Technologies, Inc. Mask-pattern determination using topology types
US7705028B2 (en) 2005-12-19 2010-04-27 Glaxosmithkline Llc Farnesoid X receptor agonists
US8722649B2 (en) 2007-06-15 2014-05-13 University Of Utah Research Foundation Alpha-chloro and alpha-bromo phosphonate analogs of lysophosphatidic acid and methods of making and using thereof
DE102007047735A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Thiazolderivate
DE102007047737A1 (de) 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
DE102007047738A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Imidazolderivate
US8268891B1 (en) 2007-11-13 2012-09-18 University Of Memphis Research Foundation Autotaxin inhibitors
US8378100B2 (en) 2008-01-09 2013-02-19 University Of Virginia Patent Foundation Phosphonate derivatives as autotaxin inhibitors
WO2009151644A2 (en) 2008-06-13 2009-12-17 Yale University Small molecule inhibitors of autotaxin methods of use
WO2010040080A1 (en) 2008-10-03 2010-04-08 Abby Louise Parrill-Baker Mechanism-based inactivators of autotaxin
DE102008059578A1 (de) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen
JP5697601B2 (ja) 2008-12-01 2015-04-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 癌に対するオータキシン阻害剤としての２，５−ジアミノ−置換ピリド［４，３−ｄ］ピリミジン
CN102365271B (zh) 2009-04-02 2014-05-14 默克专利有限公司 作为自分泌运动因子抑制剂的杂环化合物
WO2010112124A1 (en) 2009-04-02 2010-10-07 Merck Patent Gmbh Autotaxin inhibitors
JP5591318B2 (ja) 2009-04-02 2014-09-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング オートタキシン阻害剤としてのピペリジンおよびピペラジン誘導体
US8445200B2 (en) 2009-04-15 2013-05-21 The Regents Of The University Of California Genotoxicity as a biomarker for inflammation
MX2011011958A (es) 2009-05-11 2012-02-13 Berg Biosystems Llc Metodos para el tratamiento de trastornos metabolicos utilizando cambiadores epimetabólicos, moléculas intracelulares multidimensionales o influenciadores ambientales.
AU2010250838B2 (en) 2009-05-20 2016-01-21 Eth Zurich Targeting microRNAs for metabolic disorders
US8343934B2 (en) 2009-06-30 2013-01-01 University Of Memphis Diverse lead compound autotaxin inhibitors
DE102009033392A1 (de) 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
DE102009049211A1 (de) 2009-10-13 2011-04-28 Merck Patent Gmbh Sulfoxide
WO2011049433A1 (en) 2009-10-23 2011-04-28 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Diagnosis and treatment of pruritis
WO2011053597A1 (en) 2009-10-26 2011-05-05 The University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
US8497371B2 (en) 2009-10-26 2013-07-30 University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
WO2011103430A1 (en) 2010-02-19 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
CN102822171B (zh) * 2010-03-26 2015-09-02 默克专利有限公司 作为自分泌运动因子抑制剂的苯并萘啶胺类
AU2011239386B2 (en) 2010-04-16 2015-03-19 Salk Institute For Biological Studies Methods for treating metabolic disorders using FGF
CN103201262B (zh) 2010-08-20 2016-06-01 艾米拉医药股份有限公司 自分泌运动因子抑制剂及其用途
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
WO2012100018A1 (en) 2011-01-20 2012-07-26 University Of Tennessee Research Foundation Inhibitors of autotaxin
IN2013MN01699A (es) 2011-02-18 2015-06-12 Medivation Technologies Inc
WO2012112964A2 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
EP2685976B1 (en) 2011-03-17 2017-12-27 Tel HaShomer Medical Research Infrastructure and Services Ltd. Quinolone analogs for treating autoimmune diseases
EP2714680B1 (en) 2011-05-27 2015-11-25 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
GB2494154B (en) 2011-08-31 2017-11-29 Metaswitch Networks Ltd Conditional telecommunications
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
EP2771325B1 (en) 2011-10-28 2017-06-28 Inhibitaxin Limited Pyridazine derivatives useful in therapy
JP2013129632A (ja) 2011-12-22 2013-07-04 Ono Pharmaceut Co Ltd Ｅｎｐｐ２阻害化合物
US20130270634A1 (en) 2012-04-12 2013-10-17 Richtek Technology Corporation High voltage device and manufacturing method thereof
SI2861566T1 (sl) 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
WO2014031170A1 (en) 2012-08-22 2014-02-27 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
SG11201500572YA (en) 2012-09-25 2015-02-27 Hoffmann La Roche New bicyclic derivatives
WO2014097151A2 (en) 2012-12-19 2014-06-26 Novartis Ag Autotaxin inhibitors
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
TWI499591B (zh) 2013-01-11 2015-09-11 Lilly Co Eli 雙環嘧啶化合物
WO2015042053A1 (en) 2013-09-17 2015-03-26 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
US9951026B2 (en) 2013-09-17 2018-04-24 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
WO2015048301A1 (en) 2013-09-26 2015-04-02 Pharmakea, Inc. Autotaxin inhibitor compounds
CU24381B1 (es) 2013-11-05 2019-02-04 Bayer Cropscience Ag Benzamidas sustituidas para controlar artrópodos
CL2016001118A1 (es) 2013-11-22 2016-12-02 Basf Se Compuestos heterocíclicos de n-acilimino
JP6449283B2 (ja) 2013-11-22 2019-01-09 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ Ｎ−アシルイミノ複素環式化合物
MX2016006688A (es) 2013-11-22 2016-11-29 Pharmakea Inc Inhibidores tetraciclicos de autotaxina.
PT3071561T (pt) 2013-11-22 2021-06-25 Sabre Therapeutics Llc Compostos inibidores de autotaxina
US9051320B1 (en) * 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
CA2986759C (en) 2015-05-27 2025-06-17 Sabre Therapeutics Llc AUTOTAXIN INHIBITORS AND THEIR USES

Also Published As

Publication number Publication date
NI201600071A (es) 2016-09-21
BR112016010220A2 (pt) 2018-05-02
IL245383B (en) 2019-11-28
US11344533B2 (en) 2022-05-31
CR20160289A (es) 2016-09-27
RS62027B1 (sr) 2021-07-30
SI3071561T1 (sl) 2021-11-30
ZA202005029B (en) 2022-02-23
US10688081B2 (en) 2020-06-23
CR20190394A (es) 2019-10-29
ES2875899T3 (es) 2021-11-11
AU2014352888B2 (en) 2019-05-09
MX2020009780A (es) 2020-10-12
US20160235713A1 (en) 2016-08-18
US11779568B2 (en) 2023-10-10
MY182095A (en) 2021-01-18
AU2019213425A1 (en) 2019-08-29
JP6501367B2 (ja) 2019-04-17
US20180243267A1 (en) 2018-08-30
WO2015077503A1 (en) 2015-05-28
EP3878848A1 (en) 2021-09-15
LT3071561T (lt) 2021-08-25
PH12016500862B1 (en) 2020-12-09
EA030068B1 (ru) 2018-06-29
KR20160079082A (ko) 2016-07-05
HRP20210957T1 (hr) 2021-09-17
NZ720478A (en) 2022-02-25
US20160374991A1 (en) 2016-12-29
AU2019213425B2 (en) 2021-01-07
EA201690881A1 (ru) 2016-12-30
HUE055213T2 (hu) 2021-11-29
CY1124407T1 (el) 2022-07-22
US9468628B2 (en) 2016-10-18
EP3071561A1 (en) 2016-09-28
PL3071561T3 (pl) 2021-11-08
US9999615B2 (en) 2018-06-19
IL270168B (en) 2022-02-01
CL2016001231A1 (es) 2017-01-20
SMT202100531T1 (it) 2021-11-12
EP3071561A4 (en) 2017-04-12
CN105793253B (zh) 2019-08-23
JP2016537389A (ja) 2016-12-01
ZA201603083B (en) 2022-03-30
CN110372671B (zh) 2023-02-21
HK1226075A1 (zh) 2017-09-22
PH12016500862A1 (en) 2016-07-18
CA2930737C (en) 2023-02-21
US9334261B2 (en) 2016-05-10
WO2015077503A8 (en) 2015-07-16
US20160046614A1 (en) 2016-02-18
CA2930737A1 (en) 2015-05-28
MX2016006623A (es) 2017-03-10
BR112016010220B1 (pt) 2023-05-09
AU2014352888A1 (en) 2016-06-09
KR102367876B1 (ko) 2022-02-24
EP3071561B1 (en) 2021-03-24
PE20160654A1 (es) 2016-07-15
CN105793253A (zh) 2016-07-20
KR102515248B1 (ko) 2023-03-29
KR20220027276A (ko) 2022-03-07
IL245383A0 (en) 2016-06-30
CN110372671A (zh) 2019-10-25
US12268668B2 (en) 2025-04-08
US20200268713A1 (en) 2020-08-27
DK3071561T3 (da) 2021-06-21
PT3071561T (pt) 2021-06-25
US20220265608A1 (en) 2022-08-25
US20240189281A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX374452B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
DOP2017000048A (es) Compuestos aminopirimidinilo como inhibidores de jak.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
MX378273B (es) Compuestos activos hacia bromodominios.
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
BR112016023815A2 (pt) composições tópicas para o alívio da dor, produção e uso
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX2016007410A (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
BR112017012504A2 (pt) derivados de piperidina como inibidores de hdac1/2
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
MX394452B (es) Inhibicion de la actividad de olig2.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.
BR112015016391A2 (pt) carboxamidas i baseadas em pirazolil como inibidoras do canal crac
BR112015016394A2 (pt) carboxamidas ii baseadas em pirazolil como inibidoras do canal crac
PH12020500472A1 (en) Autotaxin inhibitor compounds

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: SABRE THERAPEUTICS LLC

FG Grant or registration